Context Therapeutics Inc (CNTX)
2.005
0.00 (0.00%)
USD |
NASDAQ |
Jun 28, 16:00
2.00
0.00 (0.00%)
After-Hours: 20:00
Context Therapeutics SG&A Expense (TTM): 7.008M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 7.008M |
December 31, 2023 | 7.290M |
September 30, 2023 | 7.396M |
June 30, 2023 | 7.671M |
March 31, 2023 | 7.830M |
December 31, 2022 | 7.79M |
September 30, 2022 | 7.851M |
Date | Value |
---|---|
June 30, 2022 | 6.709M |
March 31, 2022 | 5.323M |
December 31, 2021 | 3.633M |
September 30, 2021 | 2.009M |
June 30, 2021 | 1.363M |
March 31, 2021 | 1.044M |
December 31, 2020 | 0.9307M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
0.9307M
Minimum
Dec 2020
7.851M
Maximum
Sep 2022
5.275M
Average
6.859M
Median
SG&A Expense (TTM) Benchmarks
Emergent BioSolutions Inc | 351.80M |
AbbVie Inc | 13.15B |
Revance Therapeutics Inc | 297.28M |
Design Therapeutics Inc | 19.80M |
NovaBay Pharmaceuticals Inc | 12.53M |